Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact Contact Barchart
Market:
Hutchmed [China] Limited (HCM.LN)
Hutchmed [China] Limited (HCM.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
Try Excel Barchart for Excel
Alerts
Watch
Help
Go To:
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 2,417,001
  • Shares Outstanding, K 870,991
  • Annual Sales, $ 426,409 K
  • Annual Income, $ -360,835 K
  • 60-Month Beta N/A
  • Price/Sales 3.81
  • Price/Cash Flow 60.47
  • Price/Book 3.75
Trade HCM.LN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.05
  • Most Recent Earnings -0.08 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
216.120 +28.75%
on 09/08/23
284.550 -2.21%
on 09/29/23
+33.500 (+13.69%)
since 08/29/23
3-Month
185.000 +50.41%
on 07/03/23
284.550 -2.21%
on 09/29/23
+98.650 (+54.93%)
since 06/29/23
52-Week
130.000 +114.04%
on 10/24/22
337.460 -17.55%
on 01/26/23
+118.850 (+74.56%)
since 09/29/22
Free Barchart Webinars! Live educational sessions using site features to explore today's markets.

Most Recent Stories

More News
Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004 Globe Newswire - Tue Aug 9, 2022

SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited...

HCM : 16.94 (-0.06%)
HCM.LN : 278.250 (+0.27%)
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial Globe Newswire - Mon Aug 8, 2022

— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase...

HCM : 16.94 (-0.06%)
HCM.LN : 278.250 (+0.27%)
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer Globe Newswire - Sun Aug 7, 2022

— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for...

HCM : 16.94 (-0.06%)
HCM.LN : 278.250 (+0.27%)
HUTCHMED Reports 2022 Interim Results and Provides Business Updates Globe Newswire - Mon Aug 1, 2022

Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA® and ORPATHYS® growth First presentation of SAVANNAH data...

HCM : 16.94 (-0.06%)
HCM.LN : 278.250 (+0.27%)
HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China Globe Newswire - Mon Aug 1, 2022

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today...

HCM : 16.94 (-0.06%)
HCM.LN : 278.250 (+0.27%)
HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China Globe Newswire - Fri Jul 15, 2022

HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter...

HCM : 16.94 (-0.06%)
HCM.LN : 278.250 (+0.27%)
HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting Globe Newswire - Tue Jul 12, 2022

— 49% ORR amongst SAVANNAH patients with higher MET levels —...

HCM : 16.94 (-0.06%)
HCM.LN : 278.250 (+0.27%)
Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007 Globe Newswire - Tue Jul 5, 2022

SAN DIEGO and SHANGHAI and HONG KONG and SYDNEY, Australia, July 06, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED...

HCM : 16.94 (-0.06%)
HCM.LN : 278.250 (+0.27%)
HUTCHMED to Announce 2022 Half-Year Financial Results Globe Newswire - Mon Jun 27, 2022

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13)...

HCM : 16.94 (-0.06%)
HCM.LN : 278.250 (+0.27%)
HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China Globe Newswire - Wed Jun 1, 2022

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13)...

HCM : 16.94 (-0.06%)
HCM.LN : 278.250 (+0.27%)
More news for this symbol

Barchart Technical Opinion

Strong buy

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

HCM.LN Quotes API

Key Turning Points

3rd Resistance Point 298.417
2nd Resistance Point 291.483
1st Resistance Point 284.867
Last Price 278.250
1st Support Level 271.317
2nd Support Level 264.383
3rd Support Level 257.767

See More

52-Week High 337.460
Last Price 278.250
Fibonacci 61.8% 258.210
Fibonacci 50% 233.730
Fibonacci 38.2% 209.250
52-Week Low 130.000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot